• Funds breathe new life into Oxygen Biotherapeutics

By DAVID RANII
Posted on Wednesday, Jan. 25, 2012

After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.

In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...

NEW VIDEO

This new video looks at Oxycyte™ as a potential treatment for Traumatic Brain Injury and Decompression Sickness.